AUG 14, 2018 11:30 PM PDT

Single Antiplatelet Drug Reduces Risk of Blood Clots

WRITTEN BY: Nouran Amin

Image Retrieved From Unsplash, www.unsplash.com

According to the current treatment protocol, patients that undergo minimally invasive aortic heart valve replacements will likely receive two antiplatelet drugs that reduce the likelihood of developing dangerous blood clots. Now, a new meta-analysis study by Loyola Medicine has found that administering just one antiplatelet drug is sufficient enough to reduce the risk of life-threatening bleeding in comparison to two of these drugs. The study was published in the July issue of the American Journal of Cardiology and led by Verghese Mathew, MD, a renowned interventional cardiologist and chair of Loyola's division of cardiology.

The aortic valve is responsible for regulating blood flow from the hearts main pumping chamber, the left ventricle, to the body’s largest artery, the aorta. Aortic stenosis is caused by the narrowing of the aortic valve, which can cause chest pain and fatigue to many affected individuals, and severe symptoms can lead to heart failure and death. To replace a diseased aortic valve usually required an open heart surgery. But in 2011, a minimally invasive technique was developed to implant an artificial valve with a catheter. The technique is known as transcatheter aortic valve replacement (TAVR) where the catheter is inserted into an artery in the groin and is led up to the heat where the valve is placed.

Watch Video Below To Understand TAVR:

 

TAVR is commercially available in the United States. After administering TAVR, patients usually take two antiplatelets known as ‘dual-antiplatelet therapy’ to reduce the risk of developing blood clots. Commonly used antiplatelet drugs are aspirin and clopidogrel (Plavix). However, the treatments vary depending on the cardiologist assigned. Some providers prescribe their patients just one antiplatelet called the ‘mono-antiplatelet therapy’ usually when the patients have an increased concern of bleeding from the dual-antiplatelet therapy. However, in the study, Dr. Mathew and team analyzed the results of eight studies that compared mono-antiplatelet therapy to the use of dual-antiplatelet therapy. The studies examined 2,439 patients in total and in four of these studies, patients were deployed the Sapien aortic valve and in two studies, they received the CoreValve device. Finally, in two of these studies, both valves were administered. During 30 days, patients given two antiplatelet agents were 2.06 times more likely to die, 2.04 times more likely to develop life-threatening bleeding and 2.15 times more likely to undergo major vascular complications. "These data suggest a safety concern with dual-antiplatelet therapy and underscore the need for a large randomized trial to definitely address this question," Dr. Mathew and colleagues wrote.

Source: Loyola University Health System

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 27, 2020
Drug Discovery & Development
APR 27, 2020
Making Cardiac Medicine From Foxglove Plants
Foxglove plants are known to be shaped like bells and have long decorated many gardens. They belong to a genus of plants ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
Researchers Use AI to Accelerate COVID-19 Drug Development
Researchers from the National University of Singapore (NUS) have developed an artificial intelligence platform to accele ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Why Doctors are Repurposing Drugs to Treat COVID-19
Creating a drug from scratch is a lengthy process. Often taking years, given the rate of infection and deadliness of COV ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
Can Chinese Drug Cure COVID-19 Without Vaccine?
Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking C ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
Loading Comments...